₩37,350.00 ($27.81)

-100.00 (-0.27%)

Weekly Expected Move ±1.0%

₩36618 ₩36984 ₩37350 ₩37716 ₩38082

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Strong Sell · Power 30 · ₩177.8B mcap · 2M float · 0.262% daily turnover

Revenue

$959.0B +0.1% ▲

5Y CAGR: +2.2%

Gross Profit

$415.9B -6.5% ▼

5Y CAGR: +0.1%

Operating Income

$58.3B +64.2% ▲

5Y CAGR: -8.2%

Net Income

$40.4B +20.3% ▲

5Y CAGR: -12.5%

EPS (Diluted)

$8422.78 +19.3% ▲

5Y CAGR: -11.7%

EBITDA

$102.3B -1.9% ▼

5Y CAGR: -5.0%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$926.0B	$909.0B	$879.8B	$957.8B	$959.0B
YoY Growth	+7.9%	-1.8%	-3.2%	+8.9%	+0.1%
Cost of Revenue	$484.6B	$509.8B	$495.9B	$513.2B	$543.1B
Gross Profit	$441.4B	$399.2B	$383.9B	$444.6B	$415.9B
Gross Margin	47.7%	43.9%	43.6%	46.4%	43.4%
R&D Expenses	$20.9B	$22.7B	$23.2B	$23.2B	$0
SG&A Expenses	$318.4B	$331.8B	$327.5B	$294.1B	$0
Operating Expenses	$407.0B	$432.1B	$350.7B	$409.1B	$357.6B
Operating Income	$34.4B	-$32.9B	$33.1B	$35.5B	$58.3B
Operating Margin	3.7%	-3.6%	3.8%	3.7%	6.1%
Interest Expense	$6.2B	$10.8B	$19.6B	$20.6B	$20.7B
Income Before Tax	$27.9B	-$24.7B	$43.7B	$40.4B	$65.1B
Tax Expense	$2.1B	-$2.0B	$3.1B	$84M	$10.8B
Net Income	$16.0B	$1.1B	$47.0B	$33.6B	$40.4B
Net Margin	1.7%	0.1%	5.3%	3.5%	4.2%
EPS (Diluted)	$3212.00	$219.00	$9743.89	$7059.01	$8422.78
EBITDA	$72.5B	$13.6B	$56.1B	$104.3B	$102.3B
Shares Outstanding	5M	5M	5M	5M	5M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$232.2B	$227.1B	$246.6B	$242.2B	$234.2B	$236.0B	$240.3B	$251.2B
Cost of Revenue	$126.0B	$117.3B	$134.4B	$129.4B	$129.7B	$149.7B	$131.6B	$150.9B
Gross Profit	$106.3B	$109.8B	$112.3B	$112.7B	$104.6B	$86.3B	$108.7B	$100.2B
Gross Margin	45.8%	48.3%	45.5%	46.6%	44.6%	36.6%	45.2%	39.9%
R&D Expenses	$4.6B	$8.6B	$6.6B	$5.5B	$6.6B	$8.3B	$8.7B	$8.6B
SG&A Expenses	$89.6B	$69.9B	$90.4B	$96.2B	$54.5B	$52.6B	$59.6B	$84.4B
Operating Expenses	$98.8B	$102.8B	$100.4B	$96.2B	$86.4B	$74.6B	$89.0B	$93.6B
Operating Income	$7.5B	$6.9B	$11.9B	$16.5B	$18.1B	$11.8B	$19.7B	$6.7B
Operating Margin	3.2%	3.0%	4.8%	6.8%	7.7%	5.0%	8.2%	2.7%
Interest Expense	$5.2B	$5.1B	$5.3B	$5.1B	$5.1B	$5.2B	$5.5B	$5.5B
Income Before Tax	$4.5B	$3.1B	$8.5B	$14.8B	$28.7B	$13.1B	$20.6B	$26.5B
Tax Expense	$696M	-$3.7B	$698M	$3.5B	$8.7B	-$2.0B	$2.7B	$8.8B
Net Income	$4.7B	$4.8B	$5.9B	$10.6B	$13.4B	$10.5B	$12.9B	$16.9B
Net Margin	2.0%	2.1%	2.4%	4.4%	5.7%	4.5%	5.4%	6.7%
EPS (Diluted)	$980.00	$1013.39	$1247.44	$2217.75	$2815.00	$4561.81	$2572.82	$3382.34
EBITDA	$18.0B	$18.6B	$22.0B	$123.6B	$44.9B	-$88.2B	$30.9B	$18.2B
Shares Outstanding	5M	5M	5M	5M	5M	3M	5M	5M

001630.KS KSC